Status:
UNKNOWN
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
Lead Sponsor:
The First Affiliated Hospital of Zhejiang Chinese Medical University
Collaborating Sponsors:
Zhejiang Chinese Medical University
Conditions:
Metabolic Dysfunction-associated Fatty Liver Disease
Eligibility:
All Genders
18-75 years
Brief Summary
This is a case-control study that aims to build a predictive model for MAFLD based on machine learning.
Detailed Description
Metabolic dysfunction-associated fatty liver disease (MAFLD) also known as non-alcoholic fatty liver disease (NAFLD), is one of the most prevalent liver diseases worldwide with high prevalence and eco...
Eligibility Criteria
Inclusion
- aged 18 to 75 years;
- meeting the diagnostic criteria of MAFLD;
- no other organic lesions were found in imaging examination;
- willing and able to sign informed consent.
Exclusion
- significant drinking history (weekly alcohol consumption ≥ 140g for male, or weekly alcohol consumption ≥ 70g for female);
- presence of evidence for having hepatic steatosis, viral hepatitis, history of hepatic cancer, drug-induced liver injury, liver cirrhosis and other liver and biliary tract diseases;
- major organ malfunction, severe systemic illnesses, mental health issues, or inability to complete examination;
- pregnant or pregnancy planning female;
- missing of important clinical data.
Key Trial Info
Start Date :
June 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06061640
Start Date
June 1 2023
End Date
December 31 2024
Last Update
September 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Clinical Medical College of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China, 310003